CLINICAL TRIALS PROFILE FOR TELMISARTAN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for TELMISARTAN
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
New Formulation | NCT02262572 ↗ | Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects | Completed | Boehringer Ingelheim | Phase 1 | 2003-04-01 | Study to assess the comparative pharmacokinetics of telmisartan/HCTZ in two new formulations based on sodium salt compared to the present commercial formulation (MicardisPlus®) |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for TELMISARTAN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | Bayer | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | GlaxoSmithKline | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | Boehringer Ingelheim | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TELMISARTAN
Condition Name
Clinical Trial Locations for TELMISARTAN
Trials by Country
Clinical Trial Progress for TELMISARTAN
Clinical Trial Phase
Clinical Trial Sponsors for TELMISARTAN
Sponsor Name